Clinical study of the PROMETA Treatment Program for alcohol dependence at Center for Drug and Alcohol Program’s (CDAP) Charleston Alcohol Research Center (CARC) at the Medical University of South Carolina (MUSC), Charleston, SC
• Raymond Anton, MD; Hugh Myrick, MD; and Robert Malcolm, MD • 60-subject, double-blind, placebo-controlled study; withdrawal symptoms, alcohol use and abstinence as endpoints • Brain imaging (brain responsiveness to alcohol cues and craving activation)
• Study COMPLETED: February 2008
Clinical study of the PROMETA Treatment Program for methamphetamine dependent subjects at Research Across America, Dallas, TX
• Harold C. Urschel III, MD, MMA; psychiatrist • 88-subject, randomized, double-blind, placebo-controlled study • Changes in neurocognitive functioning during early abstinence, reduced cravings, drug-free days, efficacy of perceived disability and effect on drug-related sexual practices as endpoints
• Study COMPLETED: November 2007
Evaluation of a new alcohol, cocaine and methamphetamine treatment with court diverted individuals with Southern University, Baton Rouge, LA
• Murelle Harrison, PhD • 30-subject, single-site, open-label, intent-to-treat; self-reported drug use, weekly urine screens, test feasibility and usefulness of the data collection instruments as endpoints
• Study COMPLETED: July 2007
Evaluation of the PROMETA Treatment Program for alcohol dependence at Cedars-Sinai Medical Center, Los Angeles, CA
• Jeffrey Wilkins, MD; Vice Chairman, Department of Psychiatry and Mental Health • 30-subject, run-in, open-label, single-site study w/ 16 week follow-up on days to first drink, days drinking, days heavy drinking, cravings and QOL as endpoints • Study presented at RSA July 2007: Cognitive Performance of Subjects Undergoing Flumazenil, Hydroxyzine, and Gabapentin Treatment of Alcohol Dependence • Study presented at INS, June 2007: Neuropsychological Findings and Work Function in Alcohol Dependent Subjects
• Study COMPLETED: March 2007
An open-label study on the safety and clinical effectiveness of the PROMETA Treatment Program in treating methamphetamine dependence at Research Across America, Dallas, TX
• Harold C. Urschel III, MD, MMA; psychiatrist • 50-subject open-label study; retention, cravings, weekly urine screens, number of days abstinent as endpoints • Study presented at Urschel open label CPDD June 2006: Safety and clinical effectiveness of Prometa for treating methamphetamine dependence • Mayo Clinic Proceedings October 2007: Open-Label Study of a Proprietary Treatment Program Targeting GABAA Receptor Dysregulation in Methamphetamine Dependence • Study presented at AAAP November 2007: Drug Craving Measurement Construct and Concurrent Validity in Open-Label Study of a Proprietary Treatment Program Targeting Type A y-Aminobutyric Acid Receptor Dysregulation in Methamphetamine Dependence
